uniQure N.V. (QURE)
| Market Cap | 2.11B |
| Revenue (ttm) | 14.34M |
| Net Income (ttm) | -199.00M |
| Shares Out | 61.60M |
| EPS (ttm) | -3.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,678,969 |
| Open | 23.05 |
| Previous Close | 67.69 |
| Day's Range | 22.85 - 36.19 |
| 52-Week Range | 5.35 - 71.50 |
| Beta | 0.53 |
| Analysts | Strong Buy |
| Price Target | 67.75 (+97.58%) |
| Earnings Date | Oct 29, 2025 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ... [Read more]
Financial Performance
In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for QURE stock is "Strong Buy." The 12-month stock price target is $67.75, which is an increase of 97.58% from the latest price.
News
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data
The U.S. Food and Drug Administration (FDA) provided feedback to uniQure N.V. (NASDAQ:QURE) regarding its investigational gene therapy for Huntington's disease, causing the stock to decline on Monday.
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm.
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE
LOS ANGELES--(BUSINESS WIRE)--uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE.
UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why.
The company believes the Food and Drug Administration may deal a setback to one of its investigational therapies.
FDA says clinical data for UniQure's Huntington's disease therapy not adequate
UniQure , said on Monday its experimental gene therapy for Huntington's disease does not have adequate clinical data to support its marketing application, according to the U.S. Food and Drug Administr...
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)
uniQure (QURE) is upgraded to Buy following strong 36-month high-dose AMT-130 data for Huntington's disease, showing significant slowing of disease progression. QURE's AMT-130 demonstrated robust clin...
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood
uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent effica...
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
uniQure Announces Pricing of Upsized $300 Million Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street
UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease ge...
uniQure Stock Jumps On Positive News, But Risks Remain
uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in t...
UniQure: How QURE Stock Rises 10x To $500?
UniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II ...
Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it
A ClearPoint Neuro's medical device plays an important role in UniQure's effort to battle Huntington's disease.
uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond
uniQure N.V. achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 study. Plan for a pre-BLA meeting with the FDA in H2 2025, targeti...
uniQure Announces $200 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...
uniQure N.V. - Special Call
uniQure N.V. - Special Call Company Participants Chiara Russo Matthew Kapusta - CEO & Executive Director Dr. Walid Abi-Saab Kylie O'Keefe - Chief Customer & Strategy Officer Conference Call Participan...
QURE stock skyrockets 200% on ‘three' big news
Uniqure (NASDAQ: QURE) shares opened nearly 200% up on Wednesday – marking one of the most dramatic single-day moves in biotech this year. The surge follows a trifecta of bullish development: a breakt...
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial
uniQure N.V. QURE on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington's disease.
UniQure's brain disorder drug slows disease progression in trial
UniQure's experimental gene therapy significantly slowed the progression of a brain disorder in an early-to-mid stage study, it said on Wednesday.
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 millio...
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external co...
uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data
uniQure's lead candidate AMT-130 targets Huntington's disease with promising clinical data and potential for accelerated FDA approval, driving my continued Buy rating. The company has strong cash rese...
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~